Bisphosphonates in the treatment of osteoporosis in 1997: A review

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 10, 1997, Pages 656-678

  Francis, Roger M ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Alendronate; Bisphosphonates; Etidronate; Fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

BONE DENSITY; BONE MINERAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; ESOPHAGITIS; FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

EID: 0030670742     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-393x(97)80101-4     Document Type: Editorial

References (92)

1. Francis RM, Sutcliffe A. Implications of osteoporotic fractures in the elderly. In: Drife JO, Study JWW, eds. HRT and Osteoporosis. Proceedings of the 22nd Study Group of the Royal College of Obstetricians and Gynaecologists. Berlin: Springer-Verlag; 1990:87-93.
2. Cooper C. Epidemiology and definition of osteoporosis. In: Compston JE, ed. Osteoporosis. New Perspectives on Causes, Prevention and Treatment. London: Royal College of Physicians of London; 1996:1-10.
3. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. BMJ. 1995; 310:1507-1510.
4. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: A worldwide projection. Osteoporosis Int. 1992;2:285-289.
5. Scane AC, Sutcliffe AM, Francis RM. The sequelae of vertebral crush fractures in men. Osteoporosis Int. 1994;4:89-92.
6. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent post menopausal bone loss? A double blind controlled study. NEJM. 1987;316:173-177.
7. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fracture of the hip and lower forearm with postmenopausal use of estrogen. NEJM. 1980;303:1195-1198.
8. Kiel DP, Felson DT, Anderson JJ, et al. Hip fractures and the use of estrogen in postmenopausal women. NEJM. 1987;317:1169-1174.
9. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. NEJM. 1993;329:1141-1146.
10. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. NEJM. 1990;322:802-809.
11. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1991;1:155-161.
12. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts compared to calcium-vitamin D in the treatment of established postmenopausal osteoporosis: The FAVOS study. Osteoporosis Int. 1996;6(Suppl 1):251. Abstract.
13. Pak CYC, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow release sodium fluoride. Ann Intern Med. 1995;123:401-408.
14. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ. 1980; 280:1340-1344.
15. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 1997;82:620-628.
16. Chesnut CH, Ivey JL, Gruber HE, et al. Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. Metabolism. 1983;29:559-562.
17. Need AG, Chatterton BE, Walker CJ, et al. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas. 1986;8:275-280.
18. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
19. Lindsay R, Tohme J. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990;76:1-6.
20. Selby PL, Horsman A, Peacock M. Norethisterone as an alternative to oestrogen in the management of postmenopausal osteoporosis. In: Christiansen J, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen: Osteopress ApS; 1987:555-556.
21. Lindsay R, Hart DM, Kraszewski A. Prospective double-blind trial of synthetic steroid Org OD 14 for preventing postmenopausal osteoporosis. BMJ. 1980;280:1207-1209.
22. Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b] thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo[b] thien-3-yl][4-[2-[1-piperidinyl)ethoxy]-phenyl] methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem. 1984;27:1057-1066.
23. Draper MW, Flowers DE, Neild JA, et al. Antiestrogenic properties of raloxifene. Pharmacology. 1995;50:209-217.
24. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
25. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of Salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ. 1992;305:556-561.
26. Rico H, Henandez ER, Revilla M, Gomez-Castresana F. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner. 1992;16: 131-138.
27. 3 and calcium to prevent hip fractures in elderly women. NEJM. 1992;327:1637-1642.
28. 2 supplementation on calcium absorption in elderly women with vertebral fractures. Osteoporosis Int. 1996;6:284-290.
29. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. NEJM. 1992;326:357-362.
30. Francis RM. Oral bisphosphonates in the treatment of osteoporosis: A review. Curr Ther Res. 1995;56:831-851.
31. Francis RM, Anderson FH, Torgerson DJ. A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol. 1995;34:1167-1171.
32. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: World Health Organization; 1994.
33. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. 1995;333:1437-1443.
34. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
35. Ross PD, Davis JW, Epstein R, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
36. Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res. 1992;7:633-638.
37. Cooper C. Epidemiology and public health impact of osteoporosis. In: Reid DM, ed. Bailliere's Clinical Rheumatology-Osteoporosis. London: Bailliere Tindall; 1993;7:459-477.
38. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest. 1996;97: 2692-2696.
39. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone. 1996;18: 75-85.
40. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. 1990;323:73-79.
41. Storm T, Thamsborg G, Steinich T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
42. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
43. Chesnut C III, Watts N, Miller P, et al. Cyclical etidronate: Efficacy and safety over seven years. Osteoporosis Int. 1996;6(Suppl 1):257. Abstract.
44. Storm T, Kollerup G, Thamsborg G, et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol. 1996;23:1560-1564.
45. Valkema R, Vismans F-JFE, Papapoulos SE, et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989;5:183-192.
46. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Continuous aminobisphosphonate (pamidronate) treatment of osteoporosis: Maintained beneficial effects beyond 3 years of therapy. Osteoporosis Int. 1996;6(Suppl 1):265. Abstract.
47. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1994;79: 1595-1599.
48. Gerber V, Thiébaud D, Husi B, et al. Dose response with intravenous pamidronate (ADP) in postmenopausal osteoporosis: Comparison of 60/15, 30 and 60 mg. Osteoporosis Int. 1996;6(Suppl 1):246. Abstract.
49. Giannini S, D'Angelo A, Malvasi L, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993;14:137-141.
50. Filipponi P, Cristallini S, Rizzello E, et al. 6-year cyclical intravenous clodronate in postmenopausal osteoporosis. Effect on bone mass and vertebral fractures. Osteoporosis Int. 1996;6(Suppl 1):260. Abstract.
51. Reginster JY, Deroisy R, Denis D, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2:1469-1471.
52. Roux C, Deroisy R, Basse-Cathalinat B, et al. Prevention of early postmenopausal bone loss with oral tiludronate. Osteoporosis Int. 1996;6(Suppl 1):249. Abstract.
53. Mortensen L, Bekker P, van den Ouweland F, et al. Prevention of early postmenopausal bone loss by risedronate: A two-year study. J Bone Miner Res. 1995;10(Suppl 1):S140. Abstract.
54. Johnston CC Jr, Bekker PJ, van den Ouweland F, et al. Risedronate prevention of bone loss in early postmenopausal women. Calcif Tissue Int. 1995;56:494. Abstract.
55. McClung M, Bensen W, Bolognese M, et al. Risedronate treatment of postmenopausal women with low bone mass: Preliminary data. Osteoporosis Int. 1996;6(Suppl 1):257. Abstract.
56. Ravn P, Clemmensen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate - a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double blind, placebo-controlled dose-finding study. Osteoporosis Int. 1996;6(Suppl 1):301. Abstract.
57. Thiébaud D, Kriegbaum H, Huss H, et al. Intravenous injections of ibandronate (IB) in the treatment of postmenopausal osteoporosis. Osteoporosis Int. 1996;6(Suppl 1):94. Abstract.
58. Gonnelli S, Zacchei F, Cepollaro C, et al. Dichloromethylenebisphosphonate in postmenopausal osteoporosis. Miner Electrolyte Metab. 1990;16:234. Abstract.
59. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA. 1997;277:1159-1164.
60. Taquet AN, Clemmensen B, Zegels B, et al. A three-year double blind placebo-controlled study of risedronate in postmenopausal osteoporosis. Osteoporosis Int. 1996;6(Suppl 1): 262. Abstract.
61. Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing. 1992;21:139-141.
62. Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. 1994;87:200-202.
63. Reid IR. Steroid osteoporosis. Osteoporosis Int. 1993;3(Suppl 1):S144-S146.
64. LoCascio V, Bonucci E, Imbimbo E, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39-51.
65. Reid IR, King AR, Alexande CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-hydroxypropylidene)-1,1,disphosphonate (APD). Lancet. 1988;1:143-146.
66. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 1994;33:348-350.
67. Adachi JD, Chines AA, Stephenson GF, Pack S. Intermittent cyclical therapy with etidronate in the prevention of corticosteroid-induced osteoporosis. Bone. 1997;20(Suppl 4):290. Abstract.
68. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 1995;99:235-242.
69. Pitt P, Li F, Bloom B, et al. A double-blind placebo controlled study of intermittent cyclical etidronate on bone mineral density in patients on long-term corticosteroid treatment. Bone. 1997;20(Suppl 4):232. Abstract.
70. Eastell R, Devogelaer JP, Peel NFA, et al. A double blind, placebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis. Osteoporosis Int. 1996;6(Suppl 1):96. Abstract.
71. Scane AC, Francis RM. Risk factors for osteoporosis in men. Clin Endocrinol. 1993;38: 15-16.
72. Seeman E, Melton LJ III, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med. 1983;75:977-983.
73. Francis RM, Peacock M, Marshall DH, et al. Spinal osteoporosis in men. Bone Miner. 1989;5:347-357.
74. Anderson FH, Francis RM, Bishop JC, Rawlings DA. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Age Ageing. In press.
75. Orme SM, Simpson M, Stewart SP, et al. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Clin Endocrinol. 1994;41:245-250.
76. Geusens P, Vanhoof J, Nijs J, et al. Heterogeneity of male osteoporosis: Effect of cyclic treatment with etidronate and calcium. Osteoporosis Int. 1996;6(Suppl 1):285. Abstract.
77. Dargie R, Gallagher S, Thompson G, et al. Response of males with osteoporosis to intermittent cyclical therapy with etidronate/calcium over 3 to 5 years. In: Ring EFJ, Elvins DM, Bhalla AK, eds. Current Research in Osteoporosis and Bone Mineral Measurement IV: 1996. London: British Institute of Radiology; 1996:140. Abstract.
78. Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate therapy: Bone histomorphometry and clinical correlates. J Bone Miner Res. 1994;9(Suppl 1):S136. Abstract.
79. Miller PD, Ericksen AL. Long-term intermittent cyclical etidronate (ICT) for postmenopausal osteoporosis (PMO). Calcif Tissue Int. 1995;56(Suppl 5):493. Abstract.
80. Steiniche T, Storm T, Thamsborg G, et al. Histomorphometric evaluation of bone biopsies after long-term cyclical etidronate treatment. 4th International Symposium on Osteoporosis, Hong Kong; 1993:25. Abstract.
81. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. BMJ. 1986;292:1227-1229.
82. Meunier PJ. Effects of long-term alendronate treatment on bone histomorphometry in postmenopausal osteoporosis. Osteoporosis Int. 1996;6(Suppl 1):310. Abstract.
83. Arlot MC, Meunier PJ, Chavassieux P, et al. Bone histomorphometry in long-term studies of alendronate in postmenopausal osteoporosis. Osteoporosis Int. 1996;6(Suppl 1):261. Abstract.
84. Langdahl B, Eriksen EF, Mortensen L, et al. Histomorphometry from a three-year risedronate bone loss prevention study. J Bone Miner Res. 1995;10(Suppl 1):S199. Abstract.
85. Fleish H. The use of bisphosphonates in osteoporosis. Br J Clin Pharmacol. 1994;48:323-326.
86. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
87. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
88. Hannuniemi R, Lauren L, Puolijoki H. Clodronate: An effective agent for the treatment of increased bone resorption. Drugs Today. 1991;27:375-390.
89. Masud T, Francis RM. Adverse effects of drugs for bone disease. Adverse Drug React Bull. 1992;155:583-586.
90. Fitton A, Mc Tavish D. Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1991;41:289-318.
91. Bonnameaux HM, Shifferli J, Montani JF, et al. Renal failure associated with intravenous bisphosphonates. Lancet. 1983;1:471. Letter.
92. Yap AS, Hockings GI, Fleming SJ, Khafagi FA. Use of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene bisphosphonate for the treatment of hypercalcaemia in patients with renal impairment. Clin Nephrol. 1990;34:225-229.